Roche and Prothena are advancing Prazinezumab to Phase 3 for Parkinson’s, despite mixed Phase 2 results, due to promising ...

The Swiss drugmaker said it was “encouraged” by the signs of effectiveness of the drug, developed by biotech Prothena, showed ...

Roche and Prothena are forging ahead to late-stage studies for their investigational Parkinson’s disease antibody ...

Roche has announced that it will be advancing its Prothena-partnered investigational Parkinson’s disease (PD) drug ...

Roche RHHBY announced that it will advance pipeline candidate prasinezumab into phase III development for early-stage ...

Prothena’s Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's Disease ...

Citizens JMP lowered the firm’s price target on Prothena Corporation plc (NASDAQ:PRTA) to $29 from $78 but kept an Outperform ...

Prothena shares fell after the company reported unfavorable trial results and said it would shrink its workforce. The stock was down 27% to $4.81 in pre-market trading Tuesday.

Today, we discuss one of these in greater detail. Prothena's program, Prasinezumab, in early Parkinson's disease is the first potentially disease-modifying antibody to demonstrate signals of ...

Shares of late-stage clinical biotechnology Prothena PRTA surged 88.7% in a year against the industry’s decline of 12.6%. The significant surge is mostly attributable to Prothena’s robust ...

For Prothena (NASDAQ: PRTA), a huge wave of attention has also come from investors since the start of the year. But has its stock price gone too high too fast? Or is this just a sign of more gains ...

DUBLIN--(BUSINESS WIRE)--Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation ...